Assenagon Asset Management S.A. Acquires New Shares in Adaptive Biotechnologies Corporation $ADPT

Assenagon Asset Management S.A. bought a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 44,488 shares of the company’s stock, valued at approximately $666,000.

Other institutional investors also recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Adaptive Biotechnologies in the 2nd quarter valued at $134,000. Caxton Associates LLP acquired a new position in Adaptive Biotechnologies during the first quarter worth approximately $93,000. Citizens Financial Group Inc. RI acquired a new position in shares of Adaptive Biotechnologies in the second quarter valued at $172,000. Ameritas Investment Partners Inc. boosted its holdings in shares of Adaptive Biotechnologies by 35.2% during the second quarter. Ameritas Investment Partners Inc. now owns 15,258 shares of the company’s stock worth $178,000 after acquiring an additional 3,972 shares during the period. Finally, Captrust Financial Advisors increased its position in Adaptive Biotechnologies by 7.6% during the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after buying an additional 1,119 shares during the period. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Harlan S. Robins sold 10,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $16.61, for a total transaction of $166,100.00. Following the transaction, the insider owned 1,232,312 shares in the company, valued at approximately $20,468,702.32. This represents a 0.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Hershberg sold 22,968 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $16.00, for a total value of $367,488.00. Following the completion of the transaction, the director owned 46,722 shares in the company, valued at approximately $747,552. The trade was a 32.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 1,216,133 shares of company stock valued at $20,882,134. 6.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Guggenheim assumed coverage on shares of Adaptive Biotechnologies in a research report on Tuesday, September 30th. They issued a “buy” rating and a $20.00 target price for the company. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective for the company. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, October 8th. Finally, BTIG Research increased their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average target price of $17.11.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock opened at $16.68 on Friday. The stock has a market capitalization of $2.55 billion, a PE ratio of -30.89 and a beta of 2.20. Adaptive Biotechnologies Corporation has a one year low of $5.91 and a one year high of $20.76. The business’s 50 day simple moving average is $16.62 and its 200 day simple moving average is $13.84.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The company had revenue of $93.97 million during the quarter, compared to analysts’ expectations of $58.76 million. During the same period in the prior year, the company posted ($0.22) earnings per share. Adaptive Biotechnologies’s revenue for the quarter was up 102.4% compared to the same quarter last year. As a group, research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.